10 at 10: These ASX stocks are riding like the wind this morning
News
News
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Code | Name | Last | % | Volume |
---|---|---|---|---|
CGB | Cann Global Limited | 0.005 | 25 | 2530198 |
IXR | Ionic Rare Earths | 0.016 | 23 | 22209301 |
LSH | Lifespot Health Ltd | 0.06 | 22 | 1722345 |
PPY | Papyrus Australia | 0.017 | 21 | 848392 |
RAN | Range International | 0.017 | 21 | 1583075 |
RWD | Reward Minerals Ltd | 0.17 | 21 | 328021 |
MLS | Metals Australia | 0.003 | 20 | 418333 |
MNB | Minbos Resources Ltd | 0.003 | 20 | 3000000 |
ICU | Isentric Ltd. | 0.11 | 20 | 4442689 |
EMT | Emetals Limited | 0.021 | 17 | 2396793 |
Potash stock Reward Minerals (ASX:RWD) obtained commonwealth environmental approval for its Lake Disappointment Potash project.
Lifespot Health (ASX:LSH) and Papyrus (ASX:PPY) both rose with news of capital raisings. Lifespot’s announcement was accompanied by a sales update.
Code | Name | Last | % | Volume |
---|---|---|---|---|
CML | Chase Mining Limited | 0.016 | -50 | 10518970 |
MSB | Mesoblast Limited | 3.08 | -39 | 12019062 |
ANW | Aus Tin Mining | 0.001 | -33 | 5636362 |
ECT | Env Clean Tech Ltd. | 0.001 | -33 | 610000 |
PSL | Paterson Resources | 0.003 | -25 | 500000 |
NWM | Norwest Minerals | 0.12 | -23 | 136172 |
CZL | Cons Zinc Ltd | 0.004 | -20 | 149999 |
CZN | Corazon Ltd | 0.002 | -20 | 1882333 |
BUX | Buxton Resources Ltd | 0.075 | -17 | 192585 |
BSM | Bass Metals Ltd | 0.003 | -14 | 3857500 |
Gold play Chase Mining (ASX:CML) fell after exploration results that left even the company disappointed.
Biotech Mesoblast (ASX:MSB) also dropped after being ordered by the FDA to conduct another clinical trial.